Ultime notizie per CytoSorbents (NASDAQ:CTSO) Azioni

CytoSorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

CytoSorbents Corp

<p>D. Boral Capital  analyst Jason Kolbert   maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.</p>


News

Price Target

Analyst Ratings

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

<p>HC Wainwright &amp; Co.  analyst Sean Lee   reiterates CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Neutral and maintains $1 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target

<p>EF Hutton  analyst Jason Kolbert   maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.</p>


EF Hutton Maintains Buy on CytoSorbents, Maintains $10 Price Target

<p>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 80.95 percent increase over losses of $(0.21) per share from the same period last year.  The company reported quarterly sales of $9.390 million which missed the analyst consensus estimate of $10.181 million by 7.77 percent.  This is a 6.57 percent increase over sales of $8.811 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

CytoSorbents Q3 2024 GAAP EPS $(0.04) Beats $(0.06) Estimate, Sales $9.390M Miss $10.181M Estimate

CytoSorbents Submits Health Canada Medical Device License Application f\For DrugSorb-ATR , Concurrent With MDSAP Certification Receipt

<p>5 analysts have expressed a variety of opinions on CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.2, with a high estimate of $10.00 and a low estimate of $1.00. Observing a 5.81% increase, the current average has risen from the previous average price target of $7.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729609267_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of CytoSorbents among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CytoSorbents. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for CytoSorbents's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into CytoSorbents's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CytoSorbents analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know CytoSorbents Better</h2>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>CytoSorbents: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> CytoSorbents's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>9.53%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-46.86%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> CytoSorbents's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-23.23%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-8.25%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.6</strong>, CytoSorbents faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 5 Ratings For CytoSorbents

<p>During the last three months, 5 analysts shared their evaluations of CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $8.2, a high estimate of $10.00, and a low estimate of $1.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $7.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729602044_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of CytoSorbents among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>EF Hutton</td>
<td>Announces</td>
<td>Buy</td>
<td>$10.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CytoSorbents. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of CytoSorbents's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CytoSorbents's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CytoSorbents analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About CytoSorbents</h2>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>CytoSorbents: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, CytoSorbents showcased positive performance, achieving a revenue growth rate of <strong>9.53%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> CytoSorbents's net margin excels beyond industry benchmarks, reaching <strong>-46.86%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> CytoSorbents's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-23.23%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-8.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.6</strong>, CytoSorbents faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts

<p>&nbsp;DrugSorb-ATR is an investigational medical device, to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta, AstraZeneca) undergoing coronary artery bypass graft (CABG) surgery.</p>


Health Care

General

The FDA Has Accepted Cytosorbents' De Novo Medical Device Application For DrugSorb-ATR And Initiated Substantive Review, The Company Anticipates An FDA Decision In 2025

WIIM

CytoSorbents shares are trading lower. The company announced it submitted its drugsorb-ATR medical device de novo marketing application to the FDA.

CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery

<p>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent.  The company reported quarterly sales of $9.89 million which beat the analyst consensus estimate of $9.68 million by 2.25 percent.  This is a 5.03 percent increase over sales of $9.42 million the same period last year.</p>


CytoSorbents Q2 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $9.89M Beat $9.68M Estimate

<p>Concurrently, Kathleen P. Bloch, CytoSorbents&#39; current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective transition.</p>


Management

CytoSorbents Appoints Peter J. Mariani As CFO, Effective August 14, 2024

<p>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent.  The company reported quarterly sales of $9.895 million which beat the analyst consensus estimate of $9.678 million by 2.25 percent.  This is a 5.03 percent increase over sales of $9.421 million the same period last year.</p>


CytoSorbents Q2 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $9.895M Beat $9.678M Estimate

Cytosorbents shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and announced a price target of $10.

<p>EF Hutton  analyst Jason Kolbert   initiates coverage on CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy rating and announces Price Target of $10.</p>


Initiation

EF Hutton Initiates Coverage On CytoSorbents with Buy Rating, Announces Price Target of $10

CytoSorbents spikes on FDA submission for DrugSorb-ATR

CytoSorbents (CTSO) announced the U.S. Food and Drug Administration, FDA, has accepted its De Novo medical device application for DrugSorb-ATR and ...

CytoSorbents announces FDA has accepted De Novo medical device application

CytoSorbents rises as FDA accepts application for device to reduce bleeding risk in bypass surgery

CytoSorbents (CTSO) announced the submission of its DrugSorb ATR Medical Device License, MDL, application to Health Canada on November 1, 2024, con...

CytoSorbents submits Health Canada MDL application for DrugSorb ATR

Cytosorbents GAAP EPS of -$0.08 misses by $0.02, revenue of $9.39M misses by $0.79M

Reports Q3 revenue $8.61M, consensus $10.18M. "I am pleased with the progress we made this quarter. Our topline performance is a testament to the i...

CytoSorbents reports Q3 adjusted EPS (8c), consensus (6c)

Cytosorbents Corp ( ($CTSO) ) has released its Q3 earnings. Here is a breakdown of the information Cytosorbents Corp presented to its investors. Cy...

CytoSorbents Corporation's Q3 2024 Financial Highlights

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

Analyst Sean Lee CFA of H.C. Wainwright maintained a Hold rating on Cytosorbents (CTSO – Research Report), retaining the price target of $1.00. Sea...

Balanced Hold Rating Amid Revenue Miss and Strategic Initiatives at CytoSorbents

CytoSorbents (CTSO) and Converge Biotech announce a new strategic collaboration where the two companies seek to expand their combined market reach ...

CytoSorbents, Converge Biotech announce strategic partnership

AZNCF

Press Releases

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

Markets

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

Comments

CytoSorbents

Notizie

Ultime notizie per CytoSorbents (NASDAQ:CTSO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO